Buruli ulcer disease: prospects for a vaccine (original) (raw)
References
Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PLC (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7:1295–1304. doi:10.1111/j.1462-5822.2005.00557.x ArticlePubMedCAS Google Scholar
Aujoulat I, Huguet-Ribas MP, Koita Y (1996) Buruli ulcer: an ignored public health problem. Dev Sante 125:22–30 (in French) Google Scholar
Bahr GM, Chugh TD, Behbehani K, Shaaban MA, Abdul-Aty M, Al Shimali B, Siddiqui Z, Gabriel M, Rook GA, Stanford JL (1987) Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Tubercle 68:105. doi:10.1016/0041-3879(87)90025-0 ArticlePubMedCAS Google Scholar
Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan BJ, Besra GS (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420–14222. doi:10.1126/science.276.5317.1420 ArticlePubMedCAS Google Scholar
Buntine J, Crofts K (eds) (2001) Buruli ulcer: management of Mycobacterium ulcerans disease. World Health Organization, Geneva Google Scholar
Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J (2007) Promising clinical efficacy of streptomycin–rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51:4029–4035. doi:10.1128/AAC.00175-07 ArticlePubMedCAS Google Scholar
Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P et al (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7:1187–1196. doi:10.1111/j.1462-5822.2005.00546.x Google Scholar
Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, Demangel C (2006) Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect 8:2075–2081. doi:10.1016/j.micinf.2006.03.009 ArticlePubMedCAS Google Scholar
Coutanceau E, Decalf J, Martino A, Babon A, Winter N et al (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204:1395–1403. doi:10.1084/jem.20070234 ArticlePubMedCAS Google Scholar
Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F (2003) First case of Mycobacterium ulcerans disease (Buruli Ulcer) that followed a human bite. Clin Infect Dis 36:e67–e68. doi:10.1086/367660 ArticlePubMed Google Scholar
Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, Dramaix M, Portaels F (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 9(12) 1297–1304 Google Scholar
Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F (2005) Buruli ulcer recurrence, Benin. Emerg Infect Dis 11:584–589 PubMed Google Scholar
Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, Meyers W, Dramaix M (2006) Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 12:1325–1331 PubMed Google Scholar
Demangel C, Stinear TP, Cole ST (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7:50–60. doi:10.1038/nrmicro2016 ArticlePubMedCAS Google Scholar
Diaz D, Dobeli H, Yeboah-Manu D, Mensah-Quainoo E, Friedlein A et al (2006) Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol 13:1314–1321. doi:10.1128/CVI.00254-06 ArticlePubMedCAS Google Scholar
Dobos KM, Spotts EA, Marston BJ, Horsburgh CR Jr, King CH (2000) Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis 6:158–164 PubMedCAS Google Scholar
George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854–857. doi:10.1126/science.283.5403.854 ArticlePubMedCAS Google Scholar
Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM (2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70:5562–5567. doi:10.1128/IAI.70.10.5562-5567.2002 ArticlePubMedCAS Google Scholar
Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD (2003) Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis 36:1076–1077. doi:10.1086/368315 ArticlePubMed Google Scholar
Grietens KP, Um Boock A, Peeters H, Hausmann-Muela S, Toomer E, Ribera JM (2008) It is me who endures but my family that suffers: social isolation as a consequence of the household cost burden of Buruli ulcer free of charge hospital treatment. PLoS Negl Trop Dis 2:e321. doi:10.1371/journal.pntd.0000321 ArticlePubMed Google Scholar
Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25:447–454. doi:10.1039/b803101k ArticlePubMedCAS Google Scholar
Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C (2008) Mycolactone diffuses from _Mycobacterium ulcerans_-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2:e325. doi:10.1371/journal.pntd.0000325 ArticlePubMedCAS Google Scholar
Johnson RC, Sopoh GE, Boko M, Zinsou C, Gbovi J, Makoutode M, Portaels F (2005) Distribution de l’infection à Mycobacterium ulcerans (ulcère de Buruli) dans la commune de Lalo au Bénin. Trop Med Int Health 10:863–871. doi:10.1111/j.1365-3156.2005.01465.x ArticlePubMedCAS Google Scholar
Kiszewski AE, Becerril E, Aguilar LD, Kader IT, Meyers WM, Portaels F, Hernandez PR (2006) The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 143:445–451. doi:10.1111/j.1365-2249.2006.03020.x ArticlePubMedCAS Google Scholar
Lagarrigue V, Portaels F, Meyers WM, Aguiar J (2000) Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin. Med Trop 60:262–266 CAS Google Scholar
Launois P, DeLeys R, Niang MN, Drowart A, Andrien M, Dierckx P, Cartel JL, Sarthou JL, Van Vooren JP, Huygen K (1994) T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect Immun 62:3679–3687 PubMedCAS Google Scholar
Marston BJ, Diallo MO, Horsburgh CR Jr, Diomande I, Saki MZ, Kanga JM, Patrice G, Lipman HB, Ostroff SM, Good RC (1995) Emergence of Buruli ulcer disease in the Daloa region of Cote d’Ivoire. Am J Trop Med Hyg 52:219–224 PubMedCAS Google Scholar
Mor N, Lutsky I, Levy L (1981) Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum. Isr J Med Sci 17:236–244 PubMedCAS Google Scholar
Nackers F, Johnson RC, Glynn J, Zinsou C, Tonglet R, Portaels F (2007) Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg 77:834–836 PubMed Google Scholar
Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, Mbuagbaw J, Portaels F, Pluschke G (2004) Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 70:520–526 PubMed Google Scholar
Okenu DM, Ofielu LO, Easley KA, Guarner J, Spotts Whitney EA et al (2004) Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol 11:387–391. doi:10.1128/CDLI.11.2.387-391.2004 ArticlePubMedCAS Google Scholar
Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Filho AL, Milanezi F, Schmitt FC, Meyers WM, Portaels F, Silva MT, Pedrosa J (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73:6299–6310. doi:10.1128/IAI.73.10.6299-6310.2005 ArticlePubMedCAS Google Scholar
Pahlevan AA, Wright DJ, Andrews G, George KM, Small PL et al (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163:3928–3935 PubMedCAS Google Scholar
Phillips R, Horsfield C, Mangan JA, Laing K, Etuaful S, Awuah P, Nyarko K, Osei-Sarpong F, Biutcehr P, Lucas S, Wansbrough-Jones M (2006) Cytokine mRNA expression in _Mycobacterium ulcerans_-infected human skin and correlation with local inflammatory response. Infect Immun 74:2917–2924. doi:10.1128/IAI.74.5.2917-2924.2006 ArticlePubMedCAS Google Scholar
Portaels F, Chemlal K, Elsen P, Johnson PDR, Hayman JA, Kirkwood R, Meyers WM (2001) Mycobacterium ulcerans in wild animals. In: Collins MT, Manning B (eds) Mycobacterial infections in domestic and wild animals. Office International de Epizooties, vol 20. Scientific and Technical Review, Paris, pp 252–264
Portaels F, Johnson P, Meyers WM (eds) (2001) Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. World Health Organization, Geneva Google Scholar
Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guédénon A, Meyers WM (2002) Prophylactic effect of M_ycobacterium bovis_ BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 9:1389–1391. doi:10.1128/CDLI.9.6.1389-1391.2002 ArticlePubMedCAS Google Scholar
Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, Zinsou C, Meyers WM (2004) BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli Ulcer disease. Infect Immun 72:62–65. doi:10.1128/IAI.72.1.62-65.2004 ArticlePubMedCAS Google Scholar
Portaels F, Meyers WM, Ablordey A, Castro A, Chemlal K, De Rijk P, Elsen P, Fissette K, Fraga A, Lee R, Mahrous E, Small P, Stragier P, Torrado E, Van Aerde A, Texeira da Silva M, Pedrosa J (2008) First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2:e178. doi:10.1371/journal.pntd.0000178 ArticlePubMedCAS Google Scholar
Pouillot R, Matias G, Mbondji Wondje C, Portaels F, Valin N, Ngoss F, Njikap A, Marsollier L, Fontanet A, Eyangoh S (2007) Risk factors for Buruli ulcer disease in Cameroon. PLoS Negl Trop Dis 1:e101. doi:10.1371/journal.pntd.0000101 ArticlePubMed Google Scholar
Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, Launois P (2004) Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 72:958–965. doi:10.1128/IAI.72.2.958-965.2004 ArticlePubMedCAS Google Scholar
Quek TY, Athan E, Henry MJ, Pasco JA, Redden-Hoare J, Hughes A, Johnson PD (2007) Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis Nov 13(11):1661–1666 Google Scholar
Revill WD, Morrow RH, Pike MC, Ateng J (1973) A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2: 873–877, 95 Google Scholar
Siegmund V, Adjei O, Nitschke J, Thompson W, Klutse E, Herbinger KH, Thompson R, van Vloten F, Racz P, Fleischer B, Loescher T, Bretzel G (2007) Dry reagent-based polymerase chain reaction compared with other laboratory methods available for the diagnosis of Buruli ulcer disease. Clin Infect Dis 45:68–75. doi:10.1086/518604 ArticlePubMedCAS Google Scholar
Smith PG, Revill WDL, Lukwago E, Rykushin YP (1976) The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 70:449–457. doi:10.1016/0035-9203(76)90128-0 ArticlePubMedCAS Google Scholar
Stanford JL, Revill WD, Gunthorpe WJ, Grange JM (1975) The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 74:7–16 CAS Google Scholar
Stienstra Y, Van Der Graaf WT, te Meerman GJ, The TH, de Leij LF, van der Werf TS (2001) Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 6:554–562. doi:10.1046/j.1365-3156.2001.00746.x ArticlePubMedCAS Google Scholar
Stinear TP, Jenkin GA, Johnson PD, Davies JK (2000) Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 182:6322–6330. doi:10.1128/JB.182.22.6322-6330.2000 ArticlePubMedCAS Google Scholar
Stinear TP, Mve-Obiang A, Small PLC, Frigui W, Pryor MJ, Brosch R, Jenkin GA, Johnson PDR, Davies JK, Lee RE, Adusumilli S, Garnier T, Haydock SF, Leadlay PF, Cole ST (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 101:1345–1349. doi:10.1073/pnas.0305877101 ArticlePubMedCAS Google Scholar
Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K (2001) Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 69:5403–5411. doi:10.1128/IAI.69.9.5403-5411.2001 ArticlePubMedCAS Google Scholar
Tanghe A, Adnet PY, Gartner T, Huygen K (2007) A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 75:2642–2644. doi:10.1128/IAI.01622-06 ArticlePubMedCAS Google Scholar
Tanghe A, Danzy J-P, Pluschke G, Huygen K (2008) Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis 2:e199. doi:10.1371/journal.pntd.0000199 ArticlePubMedCAS Google Scholar
Tonjum T, Welty DB, Jantzen E, Small PL (1998) Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA–DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol 36:918–925 PubMedCAS Google Scholar
Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG et al (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75:3979–3988. doi:10.1128/IAI.00290-07 ArticlePubMedCAS Google Scholar
Van Vooren JP, Drowart A, De Bruyn J, Launois P, Millan J, Delaporte E, Develoux M, Yernault JC, Huygen K (1992) Humoral responses against the 85A and 85B antigens of Mycobacterium bovis BCG in patients with leprosy and tuberculosis. J Clin Microbiol 30:1608–1610 PubMed Google Scholar
Walsh DS, Meyers WM, Portaels FP, Lane JE, Mongkolsirichaikul D, Hussem K, Gosi P, Myint KS (2005) High rates of apoptosis in human Mycobacterium ulcerans culture-positive buruli ulcer skin lesions. Am J Trop Med Hyg 73:410–415 PubMed Google Scholar
Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, Boezen HM, Limburg PC, Van der Werf TS (2005) Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 12:125–129. doi:10.1128/CDLI.12.1.125-129.2005 ArticlePubMedCAS Google Scholar
Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56:648–661 PubMedCAS Google Scholar
World Health Organization (2000) Buruli ulcer. In: Asiedu K, Scherpbier R, Raviglione M (eds) Mycobacterium ulcerans infection. World Health Organization, Geneva Google Scholar
World Health Organization (2004) Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization, Geneva Google Scholar
World Health Organization (2008) Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally. Wkly Epidemiol Rec 83:145–156 Google Scholar
Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D et al (2006) Systematic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79:1150–1156. doi:10.1189/jlb.1005581 ArticlePubMedCAS Google Scholar